ID   COR-L23/R
AC   CVCL_2008
SY   COR-L23-R; COR-L23R
DR   CLO; CLO_0002587
DR   cancercelllines; CVCL_2008
DR   Cell_Model_Passport; SIDM01204
DR   DSMZ; ACC-883
DR   DSMZCellDive; ACC-883
DR   ECACC; 96042339
DR   Wikidata; Q54814273
RX   PubMed=3011054;
RX   PubMed=7903701;
RX   PubMed=12606785;
CC   Population: Caucasian.
CC   Doubling time: ~35-40 hours (DSMZ=ACC-883).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 10,11
ST   D16S539: 11,13
ST   D18S51: 13,16
ST   D19S433: 14
ST   D21S11: 31.2
ST   D2S1338: 23,26
ST   D3S1358: 15
ST   D5S818: 10,12
ST   D7S820: 9
ST   D8S1179: 10,13
ST   FGA: 24
ST   Penta D: 13
ST   Penta E: 12,20
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 19
DI   NCIt; C4450; Lung large cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1139 ! COR-L23
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 20
//
RX   PubMed=3011054; DOI=10.1038/bjc.1986.83;
RA   Twentyman P.R., Fox N.E., Wright K.A., Bleehen N.M.;
RT   "Derivation and preliminary characterisation of adriamycin resistant
RT   lines of human lung cancer cells.";
RL   Br. J. Cancer 53:529-537(1986).
//
RX   PubMed=7903701; DOI=10.1093/jnci/86.2.110;
RA   Barrand M.A., Heppell-Parton A.C., Wright K.A., Rabbitts P.H.,
RA   Twentyman P.R.;
RT   "A 190-kilodalton protein overexpressed in
RT   non-P-glycoprotein-containing multidrug-resistant cells and its
RT   relationship to the MRP gene.";
RL   J. Natl. Cancer Inst. 86:110-117(1994).
//
RX   PubMed=12606785; DOI=10.1124/mol.63.3.742;
RA   Briz O., Macias R.I.R., Vallejo M., Silva A., Serrano M.A.,
RA   Marin J.J.G.;
RT   "Usefulness of liposomes loaded with cytostatic bile acid derivatives
RT   to circumvent chemotherapy resistance of enterohepatic tumors.";
RL   Mol. Pharmacol. 63:742-750(2003).
//